Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

Writing this many articles certainly wasn’t one of my goals when I first started blogging about the science behind cancer, 100 seemed like the north face of the Eiger at the time! I’m not sure how many of you have been with me since the first few posts, but this seems a great opportunity to thank everyone for dropping by and reading, whether it’s your first time or you’ve been a regular for a while. All the comments and emails received have been very much appreciated.

Earlier this month, I put up a one question poll asking what sort of content you wanted to read more about and here are the results (accessed on Jan 18th):

The most popular requests were for more reviews of companies (27%), interviews with thought leaders (20%), with a fifth of those voting saying the mix was about right.  The poll is still running for those of you who missed and want your vote to count.  I’ll be re-running it later in the year to keep tabs on what readers want to see here on the blog.

The conference meeting insights will be rolling out in the newsletter, which will go out to subscribers by email occasionally.  If you haven’t signed up yet, you can add your name and email in the signup box in the right hand margin.

Over the next few days I plan on posting an interview with Dr Michael Kastan of St Judes who did a lot of stellar work on p53 and a review of Mirna Therapeutics, who have an interesting microRNA platform.

If anyone would like to suggest thought leaders or companies they would like to hear more about, please do add them in the comments below.

2 Responses to “Today is my 801st post…”

  1. Eileen O'Brien

    Congratulations! What an accomplishment to be consistently producing such quality content. Here’s to the next 801.

  2. Na_krrish

    801! great.. the number itself speaks a lot..Hands off to you…I look forward to read further posts from you..I also would like to bring your kind attention to a blog where i found an article on a recent issue in biopharma industry. The blog also contains many other articles related to biopharma. Have a look at it @ “”

Comments are closed.

error: Content is protected !!